Forest Pharmaceuticals Inc. and Forest Laboratories Inc. are facing multiple proposed class actions in which the plaintiffs allege antidepressants Celexa and Lexapro were unlawfully marketed to treat adolescent depression.
Plaintiffs Allied Services Division Welfare Fund, of Arlington Heights, Ill., and New Mexico UFCW Union’s and Employers’ Health and Welfare Trust Fund, of Albuquerque, N.M., filed the putative class actions in Massachusetts federal district court. Read the complaint here.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
